Nivolumab in combination with ipilimumab for the treatment of melanoma

R Somasundaram, M Herlyn - Expert review of anticancer therapy, 2015 - Taylor & Francis
R Somasundaram, M Herlyn
Expert review of anticancer therapy, 2015Taylor & Francis
Melanoma patients develop resistance to most therapies, including chemo-and targeted-
therapy drugs. Single-agent therapies are ineffective due to the heterogeneous nature of
tumors comprising several subpopulations. Treatment of melanoma with immune-based
therapies such as anti-cytotoxic T-lymphocyte activation-4 and anti-programmed death-1
antibodies has shown modest but long-lasting responses. Unfortunately, only subsets of
melanoma patients respond to antibody-based therapies. Heterogeneity in lymphocyte …
Melanoma patients develop resistance to most therapies, including chemo- and targeted-therapy drugs. Single-agent therapies are ineffective due to the heterogeneous nature of tumors comprising several subpopulations. Treatment of melanoma with immune-based therapies such as anti-cytotoxic T-lymphocyte activation-4 and anti-programmed death-1 antibodies has shown modest but long-lasting responses. Unfortunately, only subsets of melanoma patients respond to antibody-based therapies. Heterogeneity in lymphocyte infiltration and low frequency of anti-melanoma-reactive T-cells in tumor lesions are partly responsible for a lack of response to antibody-based therapies. Both antibodies have same biological function but they bind to different ligands at various phases of T-cell activity. Thus, combination therapy of antibodies has shown superior response rates than single-agent therapy. However, toxicity is a cause of concern in these therapies. Future identification of therapy-response biomarkers, mobilization of tumor-reactive T-cell infiltration using cancer vaccines, or non-specific targeted-therapy drugs will minimize toxicity levels and provide long-term remissions in melanoma patients.
Taylor & Francis Online